U.S. License Holder:
Revance Therapeutics, Inc.
Date of License:
September-07-2022
Last Update:
May-31-2023
FDA-Approved Indications
DAXXIFY (daxibotulinumtoixnA-lanm) is an acetylcholine release inhibitor and neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients.